obesity drug news today glp-1 2025 sep 30 Agonists Market Report 2025-2033, By Product, Molecule, and Geo 2024 was a record year

Data extraction The baseline characteristics and outcomes data were extracted using a Microsoft Excel extraction sheet by two authors, and a senior author settled disagreements

Role of GLP-1 Agonists and SGLT-2 on Diabetes and Kidney Disease Post Liver Transplant The emergence of Glucagon-like peptide-1 receptor (GLP-1) agonists and Sodium-glucose cotransporter-2 (SGLT-2) inhibitors as glucose-lowering therapies has opened new therapeutic avenues for managing patients with diabetic kidney disease

For more on this, see our guide to Ozempic Patch Reality Check: Science-Backed Treatment or Clever Marketing?, and how it is evaluated and treated at Perfect B in Doral

Naslund et al., 1999

[29] found a modest but significant reduction in headache risk with tirzepatide: by 24 months, the risk of having headaches was ~ 20% lower in the tirzepatide group compared to controls (RR 0.803, 95% CI 0.6680.966)

Emerging evidence suggests GLP-1RAs may help in: Alzheimer Disease Reduced neuroinflammation Improved neuronal survival Potential slowing of cognitive decline Parkinson Disease Neuroprotective effects Reduced oxidative stress Improved neuronal signaling This area may redefine future neuroendocrine therapeutics